Related Experiment Video
Updated: Feb 17, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.6K
Liver-directed therapy for hepatocellular carcinoma
Kazim H Narsinh1,2, David P Duncan3, Isabel G Newton3
1Division of Interventional Radiology, Department of Radiology, University of California San Diego Medical Center, 200 W. Arbor Drive #8756, San Diego, CA, 92103, USA. knarsinh@ucsd.edu.
Abdominal Radiology (New York)
|December 13, 2017
Summary
This review covers liver-directed therapies for hepatocellular carcinoma, including ablation and transarterial treatments. It details their effectiveness and patient selection for optimal outcomes.
Area of Science:
- Interventional Radiology
- Hepatobiliary Oncology
Background:
- Hepatocellular carcinoma (HCC) management relies heavily on liver-directed therapies.
- Key modalities include percutaneous ablation, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE).
Purpose of the Study:
- To review liver-directed treatment options for hepatocellular carcinoma.
- To discuss the efficacy and patient selection criteria for each modality.
Main Methods:
- Review of existing literature on liver-directed therapies for HCC.
- Analysis of treatment efficacy based on disease stage and modality.
Main Results:
- Different treatment modalities offer varying efficacy depending on HCC stage.
- Combination therapies may be optimal for select patients.
- Interventional radiologists administer these image-guided procedures.
Conclusions:
- Liver-directed therapies are essential for HCC treatment.
- Careful patient selection based on disease characteristics is crucial for treatment success.
